XML 43 R28.htm IDEA: XBRL DOCUMENT v3.25.1
THE COMPANY AND BASIS OF PRESENTATION - Narrative (Details)
3 Months Ended
Apr. 23, 2024
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Reverse stock split 0.05        
Accumulated deficit   $ 634,738,000   $ 611,258,000  
Cash and cash equivalents   174,489,000 $ 29,018,000 196,177,000 $ 35,778,000
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Accumulated deficit   (634,738,000)   (611,258,000)  
Cash and cash equivalents   174,489,000 29,018,000 196,177,000 $ 35,778,000
Reversal of indirect tax liabilities   5,510,000 $ 0    
Indirect tax amounts, decrease resulting from settlement with taxing authorities   3,700,000      
Indirect tax amounts, income tax penalties and interest accrued, decrease resulting from settlement with taxing authorities   1,800,000      
Total revenues | Rezafungin          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Liabilities related to discontinued operations   0   0  
Assets related to discontinued operations   $ 0   $ 0